Routine filing of demat-remat compliance certificate for Q2 FY27
SAROJA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Saroja Pharma Industries submitted a quarterly compliance certificate under SEBI Regulation 74(5) for the period ending September 30, 2026. The certificate was issued by KFIN Technologies, the company's Registrar and Share Transfer Agent, confirming that details of shares dematerialized and rematerialized during the quarter were furnished to the stock exchanges and to both CDSL and NSDL depositories. This is a standard procedural compliance required every quarter and carries no business or financial impact.
Routine compliance filing, no material impact on operations or shareholder value. Standard quarterly regulatory requirement.